CKD, plasma lipids, and common carotid intima-media thickness: Results from the multi-ethnic study of atherosclerosis

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 11, 2012, Pages 1777-1785

  Lamprea Montealegre, Julio A ^a,b   Astor, Brad C ^c   McClelland, Robin L ^d   de Boer, Ian H ^d   Burke, Gregory L ^e   Sibley, Christopher T ^f   O'Leary, Daniel ^g   Richey Sharrett, A ^a,b   Szklo, Moyses ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; ETHNICITY; FEMALE; HUMAN; INFLAMMATION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE;

AGED; ATHEROSCLEROSIS; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL, LDL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84869104502     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02090212     Document Type: Article

References (39)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007
2. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J: The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140: 9-17, 2004
3. Muntner P, He J, Astor BC, Folsom AR, Coresh J: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities study. J Am Soc Nephrol 16: 529-538, 2005
4. FellströmBC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407, 2009
5. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
6. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 361: 2024-2031, 2003
7. Bagdade J, Casaretto A, Albers J: Effects of chronic uremia, hemodialysis, and renal transplantation on plasma lipids and lipoproteins in man. J Lab Clin Med 87: 38-48, 1976
8. Bagdade JD, Porte D Jr Bierman EL: Hypertriglyceridemia. A metabolic consequence of chronic renal failure. N Engl JMed 279: 181-185, 1968
9. de Boer IH, Astor BC, Kramer H, Palmas W, Seliger SL, Shlipak MG, Siscovick DS, Tsai MY, Kestenbaum B: Lipoprotein abnormalities associated with mild impairment of kidney function in the Multi-Ethnic Study of Atherosclerosis. Clin J Am Soc Nephrol 3: 125-132, 2008
10. de Boer IH, Astor BC, Kramer H, Palmas W, Rudser K, Seliger SL, Shlipak MG, Siscovick DS, Tsai MY, Kestenbaum B: Mild elevations of urine albumin excretion are associated with atherogenic lipoprotein abnormalities in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 197: 407-414, 2008
11. Kovesdy CP, Anderson JE, Kalantar-Zadeh K: Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: Effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 18: 304-311, 2007
12. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 291: 451-459, 2004
13. Contreras G, Hu B, Astor BC, Greene T, Erlinger T, Kusek JW, Lipkowitz M, Lewis JA, Randall OS, Hebert L, Wright JT Jr, Kendrick CA, Gassman J, Bakris G, Kopple JD, Appel LJ; African-American Study of Kidney Disease, and Hypertension Study Group: Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. J Am Soc Nephrol 21: 2131-2142, 2010
14. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP: Multi-ethnic study of atherosclerosis: Objectives and design. Am J Epidemiol 156: 871-881, 2002
15. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972
16. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC Jr, O'Leary DH, Saad MF, Tsai MY, Sharrett AR: LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 192: 211-217, 2007
17. Otvos JD: Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48: 171-180, 2002
18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
19. Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PWF, D'Agostino RB, Vasan RS, Robins SJ: Increased small low-density lipoprotein particle number: A prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113: 20-29, 2006
20. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 358: 2026-2033, 2001
21. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 364: 937-952, 2004
22. Chawla V, Greene T, Beck GJ, Kusek JW, Collins AJ, Sarnak MJ, Menon V: Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease. Clin J Am Soc Nephrol 5: 1582-1587, 2010
23. Kalantar-Zadeh K, Kovesdy CP, Derose SF, Horwich TB, Fonarow GC: Racial and survival paradoxes in chronic kidney disease. Nat Clin Pract Nephrol 3: 493-506, 2007
24. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC: Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 8: 216-224, 2002
25. Chao FC, Efron B, Wolf P: The possible prognostic usefulness of assessing serum proteins and cholesterol in malignancy. Cancer 35: 1223-1229, 1975
26. Corti MC, Guralnik JM, Salive ME, Harris T, Ferrucci L, Glynn RJ, Havlik RJ: Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med 126: 753-760, 1997
27. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG: Total cholesterol and risk of mortality in the oldest old. Lancet 350: 1119-1123, 1997
28. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC: Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 43: 1439-1444, 2004
29. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD: Malnutrition-inflammation complex syndrome in dialysis patients: Causes and consequences. Am J Kidney Dis 42: 864-881, 2003
30. Tonbul HZ, Demir M, Altintepe L, Güney I, Yeter E, Türk S, Yeksan M, Yildiz A: Malnutrition-inflammation-atherosclerosis (MIA) syndrome components in hemodialysis and peritoneal dialysis patients. Ren Fail 28: 287-294, 2006
31. Akdag I, Yilmaz Y, Kahvecioglu S, Bolca N, Ercan I, Ersoy A, Gullulu M: Clinical value of the malnutrition-inflammationatherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: A 5-year prospective study. Nephron Clin Pract 108: c99-c105, 2008
32. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 377: 2181-2192, 2011
33. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP; Ezetimibe Study Group: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 107: 2409-2415, 2003
34. Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, Griffen L, Taylor AJ: The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): Final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 55: 2721-2726, 2010
35. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E; ENHANCE Investigators: Simvastatin with or without ezetimibe in familial hypercholesterolemia. NEngl J Med 358: 1431-1443, 2008
36. Ridker PM, Cook N: Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 109: 1955-1959, 2004
37. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr; Cardiovascular Health Study Collaborative Research Group: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. NEngl J Med 340: 14-22, 1999
38. Polak JF, Pencina MJ, Pencina KM, O'Donnell CJ, Wolf PA, D'Agostino RB Sr: Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 365: 213-221, 2011
39. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M: Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis. Circulation 115: 459-467, 2007